pfizer globally recalls Oxbryta, a sickle cell disease treatment drug, due to increased risks of complications and death.
According to Reuters on September 26, USA pharmaceutical company pfizer announced on Wednesday that it will withdraw its sickle cell disease treatment drug Oxbryta from all approved markets, citing increased risks of complications and death associated with the drug. Pfizer acquired Oxbryta when it bought Global Blood Therapeutics for 5.4 billion dollars in 2022. The company reported that the therapy generated revenue of 0.328 billion dollars in 2023. The drug withdrawal occurred as the European Medicines Agency's Committee for Medicinal Products for Human Use held a "special meeting" to review pfizer's drugs beforehand. In a study of 2
Express News | Pfizer and ShangPharma Group reached a strategic cooperation.
Jefferies Maintains Pfizer(PFE.US) With Buy Rating, Cuts Target Price to $33
Jefferies Remains a Buy on Pfizer (PFE)
Express News | Pfizer : Jefferies Cuts Target Price to $33 From $35
Pfizer (PFE) Rises But Trails Market: What Investors Should Know